Thalidomide (<i>N</i>-phthaloylglutamimide&gt; in the treatment of advanced cancer

Olson, Kenneth B.; Hall, Thomas C.; Horton, John; Khung, Christiaan L.

doi:10.1002/cpt196563292

Cited by 65 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, because of significant effects observed in MM patients [1], the drug was reintroduced and approved for therapy of erythema nodosum leprosum, Kaposi sarcoma, renal cell carcinoma, prostate cancer, myelodysplastic syndromes and Waldenstrom macroglobulinemia.…”

Section: Discussionmentioning

confidence: 98%

Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide–dexamethasone

2008

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide–dexamethasone

2008

View full text Add to dashboard Cite

“…[4][5][6][7][8] This was followed by extensive studies into its mechanism of actions. [9][10][11][12][13][14] The multi-targeted mechanisms of actions of thalidomide for its anti-cancer activities, including direct cytotoxic effect on myeloma cells, its effects on modifying the microenvironment of the cancer site, and its enhancing effect on patients' anti-cancer immunity.…”

Section: Thalidomide As a Useful Adjunct Therapy/ Supplement In Myelomentioning

confidence: 99%

Supplements for immune enhancement in hematologic malignancies

Sze¹,

Chan²

2009

Hematology

View full text Add to dashboard Cite

This brief review aims to discuss the various cellular immunological aspects and related mechanisms of the use of specific components from traditional herbal medicines. We begin with lessons learned from thalidomide as an effective single drug with multiple mechanisms of action to treat multiple myeloma. Examples of "supplements" or integrative therapy will be drawn from arsenic trioxide, medicinal mushrooms including Coriolus vesicular and Ganoderma lucidum, followed by the discussion of beta-glucans affecting various immunological important cellular subsets. Different classes of compounds may enhance distinct immune cell populations that might contribute to a multi-targeted holistic effects on anti-cancer treatment. Finally, we conclude by highlighting an herbal formulation PHY906 as a potential adjunct to chemotherapy that might become one of the first US Food and Drug Administration (FDA) approved oral herbal medicines for anti-cancer adjunct treatment.

show abstract

“…It interacts with interleukins and interferons [14], down-regulates adhesion molecules involved in leucocyte migration [15] and shifts the ratio of CD4 (cluster of differentiation) to CD8 lymphocytes [16]. In the field of palliative care, reports on the use of TH date back to the 1960s [17,18,19,20]. Several reports on the use of TH with palliative and anti-angiogenic intention for patients with malignant gliomas have been published, which are summarized in table 1[21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42].…”

Section: Introductionmentioning

confidence: 99%

Thalidomide as Palliative Treatment in Patients with Advanced Secondary Glioblastoma

Hassler¹,

Sax²,

Flechl³

et al. 2014

Oncology

View full text Add to dashboard Cite

Background: For its numerous abilities including sedation, we have been using thalidomide (TH) as the ‘last therapeutic option' in patients with advanced gliomas. We noticed that a small subgroup, i.e. patients with secondary glioblastoma (GBM, whose GBM has evolved over several months or years from a less malignant glioma), survived for prolonged periods. Therefore, we retrospectively evaluated the outcomes of patients with secondary GBM treated with TH at our centre. Patients and Methods: Starting in the year 2000, we have studied 23 patients (13 females, 10 males, with a median age of 31.5 years) with secondary GBM who have received palliative treatment with TH 100 mg at bedtime. All patients had previously undergone radiotherapy and received at least 1 and up to 5 regimens of chemotherapy. Results: The median duration of TH administration was 4.0 months (range 0.8-32). The median duration of overall survival after the start of TH therapy was 18.3 months (range 0.8-57). Eleven patients with secondary GBM survived longer than 1 year. Symptomatic improvement was most prominent in the restoration of a normal sleep pattern. Conclusion: The palliative effects of TH, especially the normalization of a sleep pattern, were highly valued by patients and families. The prolongation of survival of patients with secondary GBM has not been reported previously. © 2014 S. Karger AG, Basel

show abstract

Thalidomide (N-phthaloylglutamimide> in the treatment of advanced cancer

Abstract: Thalidomide (N-phthaloylglutamimide)

Cited by 65 publications

References 0 publications

Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide–dexamethasone

Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide–dexamethasone

Supplements for immune enhancement in hematologic malignancies

Thalidomide as Palliative Treatment in Patients with Advanced Secondary Glioblastoma

Contact Info

Product

Resources

About